Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.84
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-1.20 Insider Own3.24% Shs Outstand45.12M Perf Week-7.07%
Market Cap83.02M Forward P/E- EPS next Y-1.22 Insider Trans0.00% Shs Float43.66M Perf Month-22.03%
Income-51.89M PEG- EPS next Q-0.29 Inst Own35.30% Short Float9.43% Perf Quarter-40.65%
Sales3.82M P/S21.73 EPS this Y20.36% Inst Trans-7.27% Short Ratio15.01 Perf Half Y-22.03%
Book/sh0.95 P/B1.95 EPS next Y-2.81% ROA-71.48% Short Interest4.12M Perf Year-41.03%
Cash/sh1.21 P/C1.52 EPS next 5Y- ROE-111.08% 52W Range1.70 - 5.12 Perf YTD-30.30%
Dividend Est.- P/FCF- EPS past 5Y7.19% ROI-100.41% 52W High-64.06% Beta2.01
Dividend TTM- Quick Ratio3.34 Sales past 5Y118.97% Gross Margin17.15% 52W Low8.24% ATR (14)0.16
Dividend Ex-Date- Current Ratio3.34 EPS Y/Y TTM13.22% Oper. Margin-1392.60% RSI (14)40.81 Volatility7.12% 7.93%
Employees51 Debt/Eq0.38 Sales Y/Y TTM-59.13% Profit Margin-1358.33% Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q23.32% Payout- Rel Volume0.72 Prev Close1.84
Sales Surprise60.61% EPS Surprise26.15% Sales Q/Q2988.24% EarningsNov 09 AMC Avg Volume274.29K Price1.84
SMA20-6.66% SMA50-19.20% SMA200-33.31% Trades Volume199,323 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-13-24Initiated Jefferies Buy $6
Jun-26-23Resumed Oppenheimer Outperform $10
Nov-21-22Initiated Piper Sandler Overweight $7
Jan-13-22Initiated H.C. Wainwright Buy $20
Jan-03-22Initiated Craig Hallum Buy $28
Nov-24-20Initiated Berenberg Buy $30
Apr-09-20Initiated Stifel Buy $21
Jan-28-20Initiated BTIG Research Buy $26
Jan-22-20Initiated JMP Securities Mkt Outperform $22
Feb-29-24 10:00AM
Feb-06-24 08:00AM
Dec-14-23 07:04AM
Nov-22-23 08:00AM
Nov-12-23 12:55PM
04:05PM Loading…
Nov-09-23 04:05PM
Nov-07-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 08:00AM
Sep-28-23 05:39AM
Sep-27-23 09:05AM
Sep-26-23 08:00AM
Aug-10-23 10:37AM
10:19AM
08:28AM
04:10PM Loading…
Aug-09-23 04:10PM
Aug-02-23 08:00AM
Jun-22-23 06:40AM
Jun-14-23 08:00AM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
May-26-23 06:19AM
May-25-23 05:00PM
May-15-23 08:00AM
May-09-23 05:55PM
04:35PM
May-08-23 08:00AM
May-05-23 02:24PM
May-04-23 01:56PM
Apr-25-23 08:00AM
08:00AM Loading…
Apr-12-23 08:00AM
Mar-28-23 10:45AM
Mar-24-23 07:28AM
Mar-22-23 07:37AM
Mar-21-23 04:10PM
Mar-15-23 08:00AM
Mar-01-23 08:00AM
Feb-22-23 08:00AM
Feb-16-23 10:30AM
08:00AM
Feb-14-23 05:49AM
Feb-01-23 08:00AM
Jan-23-23 08:00AM
Nov-22-22 08:00AM
Nov-17-22 09:00AM
Nov-16-22 05:33AM
Nov-14-22 04:01PM
08:20AM
Nov-10-22 09:00AM
Nov-09-22 08:00AM
Nov-07-22 08:00AM
Oct-17-22 12:18PM
Oct-05-22 08:00AM
Oct-04-22 08:00AM
Sep-07-22 08:00AM
Aug-26-22 06:21AM
Aug-23-22 04:30PM
09:55AM
Aug-22-22 08:00AM
Aug-04-22 04:30PM
06:35AM
Jul-11-22 08:00AM
Jun-27-22 10:49AM
Jun-13-22 08:00AM
Jun-02-22 06:56AM
Jun-01-22 08:00AM
May-26-22 05:00PM
May-11-22 08:00AM
May-10-22 04:30PM
11:23AM
May-06-22 08:25AM
May-05-22 09:45AM
May-04-22 06:25PM
Apr-05-22 09:09PM
Apr-04-22 09:06AM
Mar-23-22 09:25AM
Mar-19-22 08:19AM
Mar-10-22 08:00AM
Mar-09-22 05:15PM
Mar-02-22 08:00AM
Feb-24-22 05:40PM
Feb-23-22 09:00PM
Feb-15-22 08:22AM
08:00AM
Feb-13-22 06:28PM
08:46AM
Jan-27-22 05:24AM
Jan-26-22 04:01PM
Jan-20-22 08:00AM
Jan-05-22 08:00AM
Dec-30-21 05:49AM
Dec-15-21 08:00AM
Dec-06-21 08:00AM
Nov-22-21 08:00AM
Nov-15-21 05:42AM
Nov-12-21 08:00AM
Nov-10-21 08:00AM
Nov-09-21 03:00PM
Oct-21-21 12:00PM
Oct-04-21 08:00AM
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suri AnishPRESIDENT AND CSOAug 25 '23Buy2.764,00011,040135,638Aug 29 04:08 PM
PASSERI DANIEL RCHIEF EXECUTIVE OFFICERAug 14 '23Buy2.863,0008,580134,578Aug 16 04:07 PM